公司名稱: 正大企業國際有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03839 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | - ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） （股份代號：3839） 建議更改公司名稱 正大企業國際有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）謹此建 議將本公司之英文名稱由「Chia Tai Enterprises International Limited」更改為 「CPBIO Holding Company Limited」，並將本公司之中文第二名稱由「正大企業國際有限公司」更改為「正大生物 控股有限公司」（「建議更改公司名稱」）。 建議更改公司名稱之條件 待上述條件達成後，建議更改公司名稱將自百慕達公司註冊處處長將本公司新英文名稱及新中文 第二名稱記入公司登記冊（以取代本公司現有英文名稱及中文第二名稱）之日起生效。本公司其 後將向香港公司註冊處辦理所有必要之登記手續。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） （股份代號：3839） 關連交易 新建發酵設施之建設合同及項目管理合同 於二零二六年三月十六日，本公司擁有 69.7% 權益之附屬公司駐馬店華中正大訂立下列 合同，以於中國河南省駐馬店巿興建一座新發酵設施： 建設合同及項目管理合同 於二零二六年三月十六日，本公司擁有69.7%權益之附屬公司駐馬店華中正大訂立建設合 同及項目管理合同，以於中國河南省駐馬店巿興建一座新發酵設施。各合同之主要條款載 列如下： 建設合同 訂約方 (i) 駐馬店華中正大（作為項目發展商） (ii) 中建正大（作為項目承包商） (i) 建設合同 – 委聘中建正大為承包商，負責新發酵設施之建築及相關工程；及 (ii) 項目管理合同 – 委任正大漢鼎為項目經理，負責上述發展項目之管理工作。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 可換股優先股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,610,777 USD | | | 0.1 USD | | 1,261,077.7 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 12,610,777 USD | | | 0.1 USD | | 1,261,077.7 | 本月底法定/註冊股本總額： USD 80,000,000 致：香港交易及結算所有限公司 公司名稱: 正大企業國際有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股 ...

Group 1 - The chairman of Charoen Pokphand International (03839.HK), Mr. Xie Jiren, has been appointed as an executive director effective from February 24, 2026, due to his new executive role within the group [1] - Mr. Li Shaozhu has resigned as the executive director and CEO (Industrial Business) to focus on personal matters, and he will no longer serve as a member of the board's remuneration committee [1] - Ms. Kobboon Srichai has been appointed as a non-executive director of the company [1] Group 2 - Mr. Ma Deshou has been appointed as the CEO and a member of the remuneration committee following his appointment as an executive director [1] - Mr. Li Shaoqing will remain as an executive director but will no longer serve as the CEO (Biochemical Business) after Mr. Ma's appointment [1] - As of the market close on February 24, 2026, Charoen Pokphand International (03839.HK) was trading at HKD 6.68, down 0.15%, with a trading volume of 128,000 shares and a turnover of HKD 856,200 [1] Group 3 - Charoen Pokphand International has a market capitalization of HKD 1.61 billion and ranks 37th in the biopharmaceutical II industry [1] - There has been low attention from investment banks regarding this stock, with no ratings provided in the last 90 days [1]

Group 1 - The company announced a change in its executive leadership, with Mr. Xie Jiren transitioning from a non-executive director to an executive director effective February 24, 2026, to take on an executive role within the group [1] - Mr. Li Shaozhu has resigned as the executive director and CEO (Industrial Business) to focus on personal matters, and he will no longer serve as a member of the board's remuneration committee [1] - Ms. Kobboon Srichai has been appointed as a non-executive director of the company [1] Group 2 - Mr. Ma Deshou has been appointed as the CEO and a member of the remuneration committee following his appointment as an executive director [1] - As a result of Mr. Ma's appointment, Mr. Li Shaoqing will no longer serve as the CEO (Biochemical Business) but will remain as an executive director [1]

Core Viewpoint - Charoen Pokphand International (03839) reported a significant increase in revenue and profit for the fiscal year ending December 31, 2025, primarily driven by substantial growth in its biotechnology business [1] Financial Performance - The company achieved revenue of approximately $536 million, representing a year-on-year growth of 74.14% [1] - Shareholders' profit attributable to the company was $32.055 million, marking a year-on-year increase of 187.03% [1] - Basic earnings per share were reported at 12.65 cents [1] Business Growth - The notable rise in profit is attributed mainly to the remarkable growth in the company's biotechnology segment [1]

Core Viewpoint - Charoen Pokphand International (03839) reported a significant increase in revenue and profit for the fiscal year ending December 31, 2025, primarily driven by strong growth in its biotechnology business [1] Financial Performance - The company achieved revenue of approximately $536 million, representing a year-on-year growth of 74.14% [1] - Shareholders' profit attributable to the company was $32.055 million, marking a year-on-year increase of 187.03% [1] - Basic earnings per share were reported at 12.65 cents [1]

Group 1 - The core viewpoint of the article is that Zhengda Enterprise International (03839.HK) reported a significant revenue increase of 74.1% to $535.9 million for the fiscal year ending December 31, 2025, compared to $307.7 million in 2024, primarily driven by its biotechnology business [1] - The substantial revenue growth is attributed to the successful implementation of key strategies focused on developing large customer sales, with a notable contribution from the growth of immunobiological products [1] - The overall gross profit margin decreased from 15.9% in 2024 to 14.4% in 2025, indicating a shift in profitability despite revenue growth [1] Group 2 - The company's profit attributable to shareholders for 2025 was $32.1 million, up from $11.2 million in 2024, reflecting significant growth in the biotechnology segment [1]

Group 1 - The company announced changes effective from February 24, 2026, including the appointment of its chairman, Xie Jiren, as an executive director due to his new executive role within the group [1] - Li Shaozhu resigned as executive director and CEO (Industrial Business) to focus on personal matters, and he will no longer be a member of the board's remuneration committee [1] - Kobboon Srichai has been appointed as a non-executive director of the company [1] Group 2 - Current executive director Ma Deshou has been appointed as the CEO and a member of the remuneration committee [1] - Following Ma Deshou's appointment, Li Shaoqing will no longer serve as CEO (Biochemical Business) but will remain as an executive director [1]